PAT-DX1 Engineering Run Update

ASX Announcements

Patrys’ appointed Contract Development Manufacturing Organisation (CDMO) has successfully completed specification testing of PAT-DX1 drug substance produced in the recently-completed engineering run, laying strong foundations for the Company’s planned phase 1 clinical trial next year.

Specification, or batch release, testing is a necessary requirement to ensure high quality pharmaceuticals are used in GMP and clinical studies.

Click here to read today’s ASX release.